ARGENX SE【ARGX】

時価総額

PER

免疫疾患向けバイオ医薬品の有力企業。FcRn阻害薬やVYVGARTなどの治療薬を展開。2023年7月に12億ドルの公募増資、2023年6月にHYTRULO承認、2030年に第3相5剤・5万人治療目標。米国・欧州・日本中心に展開。

	2018年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Property, plant and equipment	-	-	-	-	-	44
Intangible assets	-	-	172	175	125	181
Deferred tax assets	-	-	32	79	97	924
Research and development incentive receivables	-	-	33	47	77	95
Investment in a joint venture	-	-	-	1	10	9
Prepaid expenses	-	-	-	-	-	24
Other non-current assets	-	-	55	41	40	42
Total non‑current assets	-	-	307	360	419	1,319
Inventories	-	-	109	228	311	407
Prepaid expenses	3	-	59	76	134	188
Trade and other receivables	-	-	38	276	497	904
Research and development incentive receivables	-	-	-	2	3	5
Financial assets	-	717	1,002	1,392	1,131	1,879
Cash and cash equivalents	-	576	1,335	801	2,049	1,500
Total current assets	-	-	2,543	2,774	4,124	4,883
Total assets	-	-	2,850	3,134	4,542	6,203
Share capital	-	-	6	7	7	7
Share premium	-	-	3,463	4,310	5,651	5,949
Translation differences	-	-	132	129	132	127
Retained earnings	-170	-	-1,400	-2,110	-2,405	-1,572
Other reserves	-	-	334	478	712	987
Total equity	-	-	2,534	2,814	4,098	5,498
Provisions for employee benefits	-	-	0	1	1	2
Lease liabilities	-	-	8	9	15	33
Deferred tax liabilities	-	-	6	8	5	-
Total non-current liabilities	-	-	15	18	22	34
Lease liabilities	-	-	4	3	5	7
Trade and other payables	-	-	293	296	414	650
Tax liabilities	-	-	4	3	4	13
Total current liabilities	-	-	301	302	423	670
Total liabilities	-	-	316	321	445	704
Total equity and liabilities	-	-	2,850	3,134	4,542	6,203